<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Lipids</journal-id><journal-id journal-id-type="iso-abbrev">J Lipids</journal-id><journal-id journal-id-type="publisher-id">JL</journal-id><journal-title-group><journal-title>Journal of Lipids</journal-title></journal-title-group><issn pub-type="ppub">2090-3030</issn><issn pub-type="epub">2090-3049</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25815213</article-id><article-id pub-id-type="pmc">4359845</article-id><article-id pub-id-type="doi">10.1155/2015/109158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effects of Statin versus the Combination of Ezetimibe plus Statin on Serum Lipid Absorption Markers in Patients with Acute Coronary Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Watanabe</surname><given-names>Erisa</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Yamaguchi</surname><given-names>Junichi</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Arashi</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Ogawa</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Hagiwara</surname><given-names>Nobuhisa</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Department of Cardiology, The Heart Institute of Japan, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 1628666, Japan</aff><author-notes><corresp id="cor1">*Junichi Yamaguchi: <email>j.yamaguchi0110@gmail.com</email></corresp><fn fn-type="other"><p>Academic Editor: Maurizio Averna</p></fn></author-notes><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>2015</year></pub-date><volume>2015</volume><elocation-id>109158</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2014</year></date><date date-type="rev-recd"><day>6</day><month>2</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 Erisa Watanabe et al.</copyright-statement><copyright-year>2015</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Background</italic>. The use of statins is essential for aggressive lipid-lowering treatment in acute coronary syndrome (ACS) patients with dyslipidemia. Recently, elevation of sitosterol, a lipid absorption marker, was reported to be associated with premature atherosclerosis. The purpose of the present study was to examine the impact of ezetimibe, a selective intestinal cholesterol transporter inhibitor, in ACS patients. <italic>Methods</italic>. A total of 197 ACS patients were randomized to pitavastatin + ezetimibe (<italic>n</italic> = 100) or pitavastatin (<italic>n</italic> = 97). Low-density lipoprotein cholesterol (LDL-C) and sitosterol levels were evaluated on admission and after 12 weeks. <italic>Results</italic>. After 12 weeks, the pitavastatin + ezetimibe group showed a significantly greater decrease of sitosterol (baseline versus after 12 weeks; 2.9 &#x000b1; 2.5 versus 1.7 &#x000b1; 1.0&#x02009;ng/mL, <italic>P</italic> &#x0003c; 0.001) than the pitavastatin group (2.7 &#x000b1; 1.5 versus 3.0 &#x000b1; 1.4&#x02009;ng/mL). The baseline sitosterol level was significantly higher in patients with achieved LDL-C levels &#x02265; 70&#x02009;mg/dL than in patients with levels &#x0003c; 70&#x02009;mg/dL (3.2 &#x000b1; 2.5 versus 2.4 &#x000b1; 1.3&#x02009;ng/mL, <italic>P</italic> = 0.006). <italic>Conclusions</italic>. Ezetimibe plus statin therapy in ACS patients with dyslipidemia decreased LDL-C and sitosterol levels more than statin therapy solo. Sitosterol Elevation was a predictor of poor response to aggressive lipid-lowering treatment in ACS patients.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Aggressive lipid-lowering treatment is crucial to secondary prevention for patients with acute coronary syndrome (ACS). The effectiveness of lipid-lowering therapy using 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), targeting cholesterol synthesis in the liver, in reducing the risk of coronary events in this population is firmly established [<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>].</p><p>The homeostasis of circulating cholesterol levels is modulated primarily by cholesterol synthesis and absorption. It has been suggested that the downregulation of cholesterol synthesis by statin therapy is compensated for by a rise in intestinal cholesterol absorption [<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Accordingly, the beneficial effect on low-density lipoprotein cholesterol (LDL-C) lowering and subsequent reduction of cardiovascular disease in response to statin inhibition of cholesterol synthesis would be attenuated in individuals who demonstrated a greater rebound increase in cholesterol absorption [<xref rid="B4" ref-type="bibr">4</xref>].</p><p>A previous study mentioned the possibility that lower cholesterol absorption was associated with reduced cardiovascular events among elderly patients [<xref rid="B5" ref-type="bibr">5</xref>]. Moreover, recent studies have clarified the molecular mechanisms underlying intestinal cholesterol absorption, which would be another potential therapeutic target for dyslipidemia. Ezetimibe is a selective intestinal cholesterol transporter inhibitor that selectively inhibits cholesterol absorption by blocking the Niemann-Pick C1-like 1 receptor. In patients with sitosterolemia, who might experience up to 50-fold elevations in circulating sitosterol concentrations and show premature atherosclerosis despite normal cholesterol levels, ezetimibe successfully produced significant reductions in sitosterol concentrations [<xref rid="B6" ref-type="bibr">6</xref>].</p><p>The effect of ezetimibe on plasma sitosterol concentrations in patients with ACS, who are at high risk for secondary cardiovascular events, is currently unknown. Recent reports claimed that the success rate of the recommended optional goal of LDL-C level less than 70&#x02009;mg/dL for very-high-risk patients was only 30% [<xref rid="B7" ref-type="bibr">7</xref>&#x02013;<xref rid="B9" ref-type="bibr">9</xref>]. The combination of ezetimibe and statin inhibits both cholesterol synthesis and intestinal cholesterol absorption, resulting in approximately 10&#x02013;20% greater reduction of LDL-C compared to statin alone [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>]. Accordingly, the purpose of the present study was to examine the impact of adding ezetimibe on sitosterol in statin-treated ACS patients.</p></sec><sec id="sec2"><title>2. Methods</title><p>This was an open-label, randomized, prospective study. A total of 197 consecutive ACS patients, whose LDL-C levels were greater than 100&#x02009;mg/dL, were enrolled from January 2010 to March 2013. Patients were randomized to an aggressive lipid-lowering group (pitavastatin + ezetimibe group; pitavastatin + ezetimibe 10&#x02009;mg/day, <italic>n</italic> = 100) or a conventional lipid-lowering group (pitavastatin group; pitavastatin only, <italic>n</italic> = 97). Follow-up rate was 100% and serum samples at 12 weeks were obtained from all participants. The starting dose of pitavastatin was 2&#x02009;mg and then left to the discretion of attending physicians. During the study period, the use of nonstudy antidyslipidemic agents was prohibited.</p><p>The serum lipid profile was assessed at the time of enrollment and 12 weeks after randomization in terms of total cholesterol (TC), LDL-C, triglycerides (TG), and high-density lipoprotein cholesterol (HDL-C). Levels of sitosterol and campesterol, as markers of cholesterol absorption, and lathosterol, as a cholesterol synthesis intermediate, were also measured at the time of enrollment and 12 weeks after randomization. All laboratory analyses were exclusively performed at SRL Inc., an external laboratory (Hachioji, Tokyo, Japan). LDL-C concentrations were estimated using Friedewald's formula [<xref rid="B13" ref-type="bibr">13</xref>]. The concentrations of sitosterol, campesterol, and lathosterol were measured on gas chromatography [<xref rid="B14" ref-type="bibr">14</xref>]. The impacts of ezetimibe on the changes in lipid profiles, cholesterol absorption, and synthesis markers were evaluated.</p><p>The study protocol was approved by the institutional review board and ethics committee. All participating patients provided their written, informed consent. Patient enrollment was carried out according to the principles of the Declaration of Helsinki.</p><p>Pearson correlation coefficients were used to assess the correlations between cholesterol absorption markers and individual baseline characteristics. Baseline clinical and laboratory characteristics were compared between those with and without elevated cholesterol absorption markers using two-way repeated measures ANOVA, the chi-square test, or paired and nonpaired <italic>t</italic>-tests. A value of <italic>P</italic> &#x0003c; 0.05 was considered significant. Statistical analyses were performed with statistical software (SPSS system ver. 20.0).</p></sec><sec id="sec3"><title>3. Results</title><p>The baseline characteristics of the study population are presented in <xref ref-type="table" rid="tab1">Table 1</xref>. There were no significant differences, including the major risk factors of cardiovascular disease, between the two groups, except for the percentage of ST-segment elevation myocardial infarction on admission. Pitavastatin dosages were similar in the two groups (pitavastatin + ezetimibe group versus pitavastatin group: 2.3 &#x000b1; 1.3 versus 2.1 &#x000b1; 1.1&#x02009;mg, <italic>P</italic> = 0.24).</p><p>The serum levels of LDL-C, HDL-C, TG, TC, lathosterol, sitosterol, and campesterol are shown in Figures <xref ref-type="fig" rid="fig1">1</xref> and <xref ref-type="fig" rid="fig2">2</xref>. The baseline lipid profiles were generally similar in the two groups. After 12 weeks of treatment, the serum levels of LDL-C, TC, sitosterol, and campesterol showed a significant decrease in the pitavastatin + ezetimibe group compared to the pitavastatin group.</p><p>The serum level of lathosterol decreased in both groups, with no significant difference between the groups. In terms of the serum levels of HDL-C and TG, there were no significant changes in each group.</p><p>
<xref ref-type="fig" rid="fig3">Figure 3</xref> shows the achievement rate of LDL-C less than 100&#x02009;mg/dL, which is the recommended target for high-risk patients in the Japan Atherosclerosis Society guidelines, moderate-risk patients in the Adult Treatment Panel III (ATPIII) and Japan Atherosclerosis Society guidelines, and the achievement rate of LDL-C less than 70&#x02009;mg/dL, which is the recommended target of high-risk patients in ATPIII and European Atherosclerosis Society (EAS) guidelines. In each analysis, the achievement rate was significantly higher in the pitavastatin + ezetimibe group than in the pitavastatin group.</p><p>The baseline levels of cholesterol synthesis and absorption markers according to the LDL-C levels at 12 weeks were also examined irrespective of treatment methods. The baseline levels of sitosterol and campesterol were significantly higher in patients whose LDL-C levels at 12 weeks were greater than or equal to 100&#x02009;mg/dL compared to patients whose LDL-C levels at 12 weeks were less than 100&#x02009;mg/dL. In terms of the baseline level of lathosterol, there was no significant difference (<xref ref-type="fig" rid="fig4">Figure 4(a)</xref>). The results were the same when the cut-off of LDL-C was defined as less than 70&#x02009;mg/dL at 12 weeks (<xref ref-type="fig" rid="fig4">Figure 4(b)</xref>).</p><p>Then, we performed additional analysis to examine the impact of baseline sitosterol concentration on lipid-lowering treatment (Figures <xref ref-type="fig" rid="fig5">5(a)</xref>&#x02013;<xref ref-type="fig" rid="fig5">5(d)</xref>). Sitosterol concentrations showed a left-skewed distribution, with a peak between 1.3 and 3.1&#x02009;<italic>&#x003bc;</italic>g/mL. Then, a sitosterol concentration of 2.2&#x02009;<italic>&#x003bc;</italic>g/dL was identified as the cut-off value and concentrations above this were defined as high. There were no significant differences between two treatment strategies in achievement of LDL-C less than 100&#x02009;mg/dL (Figures <xref ref-type="fig" rid="fig5">5(a)</xref> and <xref ref-type="fig" rid="fig5">5(c)</xref>). However, pitavastatin + ezetimibe group showed higher achievement of LDL-C less than 70&#x02009;mg/dL (Figures <xref ref-type="fig" rid="fig5">5(b)</xref> and <xref ref-type="fig" rid="fig5">5(d)</xref>). Moreover, in pitavastatin + ezetimibe group, there was no significant difference in achievement of LDL-C less than 70&#x02009;mg/dL between high sitosterol group and low sitosterol group (59% versus 73%, <italic>P</italic> = 0.16), whereas there was a statistical difference in pitavastatin group (22% versus 43%, <italic>P</italic> = 0.033).</p><p>No clinical adverse events potentially related to statin and ezetimibe occurred during the study period. Laboratory data showed no clinically significant alterations of hepatic enzymes or creatine phosphokinase.</p></sec><sec id="sec4"><title>4. Discussions</title><p>The primary finding in the present study was a more significant reduction in serum levels of LDL-C, sitosterol, and campesterol after 12-week treatment with pitavastatin + ezetimibe in an ACS population, compared to monotherapy with pitavastatin. This study is short-term intervention trial to clarify the correlated fluctuations of the serum levels of sitosterol with the serum levels of LDL-C in ACS patients with dyslipidemia.</p><p>Coadministration of pitavastatin + ezetimibe resulted in a 15.3% reduction of the serum LDL-C level in patients with ACS. Because the dosage of pitavastatin was similar, the degree of restoration in LDL-C synthesis was considered to be identical. Thus, inhibiting LDL-C absorption by ezetimibe would be the main reason for the decreased serum LDL-C level.</p><p>Statins are the mainstay of therapy for dyslipidemia. In patients with stable coronary heart disease, the Treating to New Target (TNT) study showed that intensive lipid-lowering therapy with 80&#x02009;mg/dL of atorvastatin per day, targeting LDL-C less than 75&#x02009;mg/dL, provided a 22% relative risk reduction compared with standard lipid-lowering therapy with 10&#x02009;mg/dL of atorvastatin per day, targeting LDL-C less than 100&#x02009;mg/dL [<xref rid="B15" ref-type="bibr">15</xref>]. However, the Lipid Treatment Assessment Project 2 showed that the success rate in reaching the more aggressive optional goal of LDL-C less than 70&#x02009;mg/dL among patients who were at very high risk of cardiovascular events was only 30% in 2007 [<xref rid="B16" ref-type="bibr">16</xref>]. In the present study, the achievement rate of LDL-C less than 70&#x02009;mg/dL, recommended in ATPIII and EAS guidelines, was 65% in the pitavastatin + ezetimibe group, which was 30% more than that in the monotherapy with pitavastatin group. Accordingly, the addition of ezetimibe to statin is considered to be a good option for aggressive lipid-lowering treatment.</p><p>Although the potential significance of plant sterol elevations in the general population is still less clear, there are several reports that a high plant sterol concentration is atherogenic and associated with coronary artery disease [<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B20" ref-type="bibr">20</xref>]. A more recent study showed that the campesterol to lathosterol ratio may be related to plaque vulnerability in the coronary artery with significant stenosis [<xref rid="B21" ref-type="bibr">21</xref>].</p><p>Previous studies have already suggested the importance of inhibiting intestinal cholesterol absorption for the primary and secondary prevention of cardiovascular events. In a subanalysis of the 4S study, the prevention of clinical events by statins was adequate in patients with lower cholesterol absorbers, whereas it was suboptimal in patients with higher cholesterol absorbers [<xref rid="B22" ref-type="bibr">22</xref>]. The results from a nested case-control analysis of the Prospective Cardiovascular Munster (PROCAM) study and the prospective study of pravastatin in the elderly at risk (PROSPER) showed that plasma sitosterol elevations are associated with an increased risk of coronary events in patients with coronary heart disease [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B23" ref-type="bibr">23</xref>].</p><p>It is important to clarify the clinical characteristics of patients who would likely benefit from their respective therapies. In hyperlipidemic patients with high level of baseline cholesterol absorption markers, previous study reported that ezetimibe added to statin therapy was the most effective strategy for LDL-C lowering [<xref rid="B24" ref-type="bibr">24</xref>]. However, no previous studies evaluated the relationship between cholesterol absorption and synthesis among ACS patients, who are thought to have greatest potential benefit from aggressive lipid-lowering treatment, targeting LDL-C less than 70&#x02009;mg/dL. The present study revealed, for the first time in ACS patients, that the baseline levels of cholesterol absorption markers were significantly higher in patients whose LDL-C levels at 12 weeks were greater than or equal to 70&#x02009;mg/dL compared to patients whose LDL-C levels at 12 weeks were less than 70&#x02009;mg/dL. Cholesterol absorption enhancement seemed to have a negative effect on the current aggressive lipid-lowering strategy. As the rationale for the above, ACS patients who show enhanced cholesterol absorption are considered reasonable targets of ezetimibe plus statin treatment.</p><p>There were some limitations in the present study. First, the number of patients in the present study was small. Second, the observation period was short. To prove the benefit in clinical outcomes, a larger study population and longer follow-up are needed.</p><p>In conclusion, ezetimibe produced significant and progressive reductions in LDL-C and cholesterol absorption markers in ACS patients with dyslipidemia. The baseline levels of cholesterol absorption markers would be useful for the selection of ACS patients who will have resistance to conventional lipid-lowering treatment.</p></sec></body><back><ack><title>Acknowledgments</title><p>The data in the present paper has already been reported at European Atherosclerosis Society Congress in 2012. This study was funded by the Japan Research Promotion Society for Cardiovascular Diseases, which had no role in the conduct of the study (Tokyo, Japan).</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lemos</surname><given-names>J. A.</given-names></name><name><surname>Blazing</surname><given-names>M. A.</given-names></name><name><surname>Wiviott</surname><given-names>S. D.</given-names></name><etal/></person-group><article-title>Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial</article-title><source><italic>The Journal of the American Medical Association</italic></source><year>2004</year><volume>292</volume><issue>11</issue><fpage>1307</fpage><lpage>1316</lpage><pub-id pub-id-type="doi">10.1001/jama.292.11.1307</pub-id><pub-id pub-id-type="other">2-s2.0-4544243333</pub-id><pub-id pub-id-type="pmid">15337732</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannon</surname><given-names>C. P.</given-names></name><name><surname>Braunwald</surname><given-names>E.</given-names></name><name><surname>McCabe</surname><given-names>C. H.</given-names></name><etal/></person-group><article-title>Intensive versus moderate lipid lowering with statins after acute coronary syndromes</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2004</year><volume>350</volume><issue>15</issue><fpage>1495</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1056/nejmoa040583</pub-id><pub-id pub-id-type="other">2-s2.0-11144355354</pub-id><pub-id pub-id-type="pmid">15007110</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>T. A.</given-names></name><name><surname>Gylling</surname><given-names>H.</given-names></name></person-group><article-title>Cholesterol absorption efficiency and sterol metabolism in obesity</article-title><source><italic>Atherosclerosis</italic></source><year>2000</year><volume>153</volume><issue>1</issue><fpage>241</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(00)00404-4</pub-id><pub-id pub-id-type="other">2-s2.0-0033790554</pub-id><pub-id pub-id-type="pmid">11058720</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthan</surname><given-names>N. R.</given-names></name><name><surname>Resteghini</surname><given-names>N.</given-names></name><name><surname>Robertson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Cholesterol absorption and synthesis markers in individuals with and without a CHD event during pravastatin therapy: insights from the PROSPER trial</article-title><source><italic>The Journal of Lipid Research</italic></source><year>2010</year><volume>51</volume><issue>1</issue><fpage>202</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1194/jlr.m900032-jlr200</pub-id><pub-id pub-id-type="other">2-s2.0-73149119778</pub-id><pub-id pub-id-type="pmid">19578163</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strandberg</surname><given-names>T. E.</given-names></name><name><surname>Tilvis</surname><given-names>R. S.</given-names></name><name><surname>Pitkala</surname><given-names>K. H.</given-names></name><name><surname>Miettinen</surname><given-names>T. A.</given-names></name></person-group><article-title>Cholesterol and glucose metabolism and recurrent cardiovascular events among the elderly: a prospective study</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2006</year><volume>48</volume><issue>4</issue><fpage>708</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2006.04.081</pub-id><pub-id pub-id-type="other">2-s2.0-33746817894</pub-id><pub-id pub-id-type="pmid">16904538</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salen</surname><given-names>G.</given-names></name><name><surname>von Bergmann</surname><given-names>K.</given-names></name><name><surname>L&#x000fc;tjohann</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>109</volume><issue>8</issue><fpage>966</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000116766.31036.03</pub-id><pub-id pub-id-type="other">2-s2.0-1442335817</pub-id><pub-id pub-id-type="pmid">14769702</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>S. M.</given-names></name><name><surname>Cleeman</surname><given-names>J. I.</given-names></name><name><surname>Bairey Merz</surname><given-names>C. N.</given-names></name><etal/></person-group><article-title>Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines</article-title><source><italic>Circulation</italic></source><year>2004</year><volume>110</volume><issue>2</issue><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000133317.49796.0e</pub-id><pub-id pub-id-type="other">2-s2.0-3142729178</pub-id><pub-id pub-id-type="pmid">15249516</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fletcher</surname><given-names>B.</given-names></name><name><surname>Berra</surname><given-names>K.</given-names></name><name><surname>Ades</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Managing abnormal blood lipids: a collaborative approach</article-title><source><italic>Circulation</italic></source><year>2005</year><volume>112</volume><issue>20</issue><fpage>3184</fpage><lpage>3209</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.105.169180</pub-id><pub-id pub-id-type="other">2-s2.0-30944460687</pub-id><pub-id pub-id-type="pmid">16286609</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morrone</surname><given-names>D.</given-names></name><name><surname>Weintraub</surname><given-names>W. S.</given-names></name><name><surname>Toth</surname><given-names>P. P.</given-names></name><etal/></person-group><article-title>Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials</article-title><source><italic>Atherosclerosis</italic></source><year>2012</year><volume>223</volume><issue>2</issue><fpage>251</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.02.016</pub-id><pub-id pub-id-type="other">2-s2.0-84864753387</pub-id><pub-id pub-id-type="pmid">22410123</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagn&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Bays</surname><given-names>H. E.</given-names></name><name><surname>Weiss</surname><given-names>S. R.</given-names></name><etal/></person-group><article-title>Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2002</year><volume>90</volume><issue>10</issue><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/s0002-9149(02)02774-1</pub-id><pub-id pub-id-type="other">2-s2.0-0037111890</pub-id><pub-id pub-id-type="pmid">12423708</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gudzune</surname><given-names>K. A.</given-names></name><name><surname>Monroe</surname><given-names>A. K.</given-names></name><name><surname>Sharma</surname><given-names>R.</given-names></name><name><surname>Ranasinghe</surname><given-names>P. D.</given-names></name><name><surname>Chelladurai</surname><given-names>Y.</given-names></name><name><surname>Robinson</surname><given-names>K. A.</given-names></name></person-group><article-title>Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2014</year><volume>160</volume><issue>7</issue><fpage>468</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.7326/m13-2526</pub-id><pub-id pub-id-type="other">2-s2.0-84897375495</pub-id><pub-id pub-id-type="pmid">24514899</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>C. M.</given-names></name><name><surname>Hoogeveen</surname><given-names>R. C.</given-names></name><name><surname>Raya</surname><given-names>J. L.</given-names></name><name><surname>Cain</surname><given-names>V. A.</given-names></name><name><surname>Palmer</surname><given-names>M. K.</given-names></name><name><surname>Karlson</surname><given-names>B. W.</given-names></name></person-group><article-title>Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20&#x02009;mg plus ezetimibe 10&#x02009;mg vs. simvastatin 40 or 80&#x02009;mg plus ezetimibe 10&#x02009;mg in high-risk patients: results of the GRAVITY randomized study</article-title><source><italic>Atherosclerosis</italic></source><year>2014</year><volume>232</volume><issue>1</issue><fpage>86</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2013.10.022</pub-id><pub-id pub-id-type="other">2-s2.0-84891594778</pub-id><pub-id pub-id-type="pmid">24401221</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedewald</surname><given-names>W. T.</given-names></name><name><surname>Levy</surname><given-names>R. I.</given-names></name><name><surname>Fredrickson</surname><given-names>D. S.</given-names></name></person-group><article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge</article-title><source><italic>Clinical Chemistry</italic></source><year>1972</year><volume>18</volume><issue>6</issue><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="other">2-s2.0-0015348189</pub-id><pub-id pub-id-type="pmid">4337382</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>T. A.</given-names></name><name><surname>Ahrens</surname><given-names>E. H.</given-names><suffix>Jr.</suffix></name><name><surname>Grundy</surname><given-names>S. M.</given-names></name></person-group><article-title>Quantitative isolation and gas&#x02014;liquid chromatographic analysis of total dietary and fecal neutral steroids</article-title><source><italic>Journal of Lipid Research</italic></source><year>1965</year><volume>6</volume><fpage>411</fpage><lpage>424</lpage><pub-id pub-id-type="other">2-s2.0-0001341631</pub-id><pub-id pub-id-type="pmid">14340676</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaRosa</surname><given-names>J. C.</given-names></name><name><surname>Grundy</surname><given-names>S. M.</given-names></name><name><surname>Waters</surname><given-names>D. D.</given-names></name><etal/></person-group><article-title>Intensive lipid lowering with atorvastatin in patients with stable coronary disease</article-title><source><italic>The New England Journal of Medicine</italic></source><year>2005</year><volume>352</volume><issue>14</issue><fpage>1425</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1056/nejmoa050461</pub-id><pub-id pub-id-type="other">2-s2.0-15944410609</pub-id><pub-id pub-id-type="pmid">15755765</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waters</surname><given-names>D. D.</given-names></name><name><surname>Brotons</surname><given-names>C.</given-names></name><name><surname>Chiang</surname><given-names>C.-W.</given-names></name><etal/></person-group><article-title>Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals</article-title><source><italic>Circulation</italic></source><year>2009</year><volume>120</volume><issue>1</issue><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.108.838466</pub-id><pub-id pub-id-type="other">2-s2.0-67651111687</pub-id><pub-id pub-id-type="pmid">19546386</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glueck</surname><given-names>C. J.</given-names></name><name><surname>Speirs</surname><given-names>J.</given-names></name><name><surname>Tracy</surname><given-names>T.</given-names></name><name><surname>Streicher</surname><given-names>P.</given-names></name><name><surname>Illig</surname><given-names>E.</given-names></name><name><surname>Vandegrift</surname><given-names>J.</given-names></name></person-group><article-title>Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives</article-title><source><italic>Metabolism: Clinical and Experimental</italic></source><year>1991</year><volume>40</volume><issue>8</issue><fpage>842</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/0026-0495(91)90013-m</pub-id><pub-id pub-id-type="other">2-s2.0-0025740575</pub-id><pub-id pub-id-type="pmid">1650421</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajaratnam</surname><given-names>R. A.</given-names></name><name><surname>Gylling</surname><given-names>H.</given-names></name><name><surname>Miettinen</surname><given-names>T. A.</given-names></name></person-group><article-title>Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2000</year><volume>35</volume><issue>5</issue><fpage>1185</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(00)00527-1</pub-id><pub-id pub-id-type="other">2-s2.0-0034116622</pub-id><pub-id pub-id-type="pmid">10758959</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhop</surname><given-names>T.</given-names></name><name><surname>Gottwald</surname><given-names>B. M.</given-names></name><name><surname>von Bergmann</surname><given-names>K.</given-names></name></person-group><article-title>Serum plant sterols as a potential risk factor for coronary heart disease</article-title><source><italic>Metabolism: Clinical and Experimental</italic></source><year>2002</year><volume>51</volume><issue>12</issue><fpage>1519</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1053/meta.2002.36298</pub-id><pub-id pub-id-type="other">2-s2.0-0036916821</pub-id><pub-id pub-id-type="pmid">12489060</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>T. A.</given-names></name><name><surname>Gylling</surname><given-names>H.</given-names></name></person-group><article-title>Cholesterol synthesis and absorption in coronary patients with lipid triad and isolated high LDL cholesterol in a 4S subgroup</article-title><source><italic>Atherosclerosis</italic></source><year>2003</year><volume>168</volume><issue>2</issue><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(03)00106-0</pub-id><pub-id pub-id-type="other">2-s2.0-0038511375</pub-id><pub-id pub-id-type="pmid">12801618</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nasu</surname><given-names>K.</given-names></name><name><surname>Terashima</surname><given-names>M.</given-names></name><name><surname>Habara</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Impact of cholesterol metabolism on coronary plaque vulnerability of target vessels: a combined analysis of virtual histology intravascular ultrasound and optical coherence tomography</article-title><source><italic>JACC: Cardiovascular Interventions</italic></source><year>2013</year><volume>6</volume><issue>7</issue><fpage>746</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2013.02.018</pub-id><pub-id pub-id-type="other">2-s2.0-84880257751</pub-id><pub-id pub-id-type="pmid">23769651</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>T. A.</given-names></name><name><surname>Gylling</surname><given-names>H.</given-names></name><name><surname>Strandberg</surname><given-names>T.</given-names></name><name><surname>Sarna</surname><given-names>S.</given-names></name></person-group><article-title>Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators</article-title><source><italic>British Medical Journal</italic></source><year>1998</year><volume>316</volume><issue>7138</issue><fpage>1127</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1136/bmj.316.7138.1127</pub-id><pub-id pub-id-type="other">2-s2.0-0032507494</pub-id><pub-id pub-id-type="pmid">9552949</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G.</given-names></name><name><surname>Cullen</surname><given-names>P.</given-names></name><name><surname>Erbey</surname><given-names>J.</given-names></name><name><surname>Ramey</surname><given-names>D. R.</given-names></name><name><surname>Kannenberg</surname><given-names>F.</given-names></name><name><surname>Schulte</surname><given-names>H.</given-names></name></person-group><article-title>Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular M&#x000fc;nster (PROCAM) study</article-title><source><italic>Nutrition, Metabolism &#x00026; Cardiovascular Diseases</italic></source><year>2006</year><volume>16</volume><issue>1</issue><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.numecd.2005.04.001</pub-id><pub-id pub-id-type="other">2-s2.0-33645519199</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thongtang</surname><given-names>N.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Schaefer</surname><given-names>E. J.</given-names></name><etal/></person-group><article-title>Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients</article-title><source><italic>Atherosclerosis</italic></source><year>2012</year><volume>225</volume><issue>2</issue><fpage>388</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2012.09.001</pub-id><pub-id pub-id-type="other">2-s2.0-84869502184</pub-id><pub-id pub-id-type="pmid">23040830</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>After 12 weeks of treatment, the serum levels of LDL-C and TC show a significant decrease in the pitavastatin + ezetimibe group compared to the pitavastatin group. In terms of the serum levels of HDL-C and TG, there are no significant changes in each group.</p></caption><graphic xlink:href="JL2015-109158.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>After 12 weeks of treatment, the serum levels of sitosterol and campesterol show a significant decrease in the pitavastatin + ezetimibe group compared to the pitavastatin group. The serum level of lathosterol decreases in both groups, but there is no significant difference between the two groups.</p></caption><graphic xlink:href="JL2015-109158.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>The achievement rate of LDL-C less than 100&#x02009;mg/dL is the recommended target of the Japan Atherosclerosis Society guidelines, and the achievement rate of LDL-C less than 70&#x02009;mg/dL is the recommended target of Adult Treatment Panel III (ATPIII) and European Atherosclerosis Society (EAS) guidelines. In each analysis, the achievement rate is significantly higher in the pitavastatin + ezetimibe group than in the pitavastatin group.</p></caption><graphic xlink:href="JL2015-109158.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>(a) The baseline levels of cholesterol synthesis and absorption markers according to the LDL-C levels at 12 weeks irrespective of treatment methods. The baseline levels of sitosterol and campesterol are significantly higher in patients whose LDL-C levels at 12 weeks are greater than or equal to 100&#x02009;mg/dL than in patients whose LDL-C levels at 12 weeks are less than 100&#x02009;mg/dL. In terms of the baseline level of lathosterol, there is no significant difference. (b) The results are the same when the cut-off of LDL-C is defined as less than 70&#x02009;mg/dL at 12 weeks.</p></caption><graphic xlink:href="JL2015-109158.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The impacts of baseline levels of sitosterol and lipid-lowering treatment strategy. (a) The achievement rate of LDL-C less than 100&#x02009;mg/dL and (b) less than 70&#x02009;mg/dL (b) in each treatment group whose baseline sitosterol is equal to or more than 2.2&#x02009;<italic>&#x003bc;</italic>g/mL. (c) The achievement rate of LDL-C less than 100&#x02009;mg/dL and (d) less than 70&#x02009;mg/dL in each treatment group whose baseline sitosterol is less than 2.2&#x02009;<italic>&#x003bc;</italic>g/mL.</p></caption><graphic xlink:href="JL2015-109158.005"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of patients in the study groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Pitavastatin + ezetimibe</th><th align="center" rowspan="1" colspan="1">Pitavastatin</th><th align="center" rowspan="2" colspan="1">
<italic>P</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 100)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 97)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (y) </td><td align="center" rowspan="1" colspan="1">65.2 &#x000b1; 11.3</td><td align="center" rowspan="1" colspan="1">66.6 &#x000b1; 12.0</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Men</td><td align="center" rowspan="1" colspan="1">70 (70.0%)</td><td align="center" rowspan="1" colspan="1">75 (77.3%)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">23.8 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">23.7 &#x000b1; 4.8</td><td align="center" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">74 (74.0%)</td><td align="center" rowspan="1" colspan="1">67 (69.1%)</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">33 (33.0%)</td><td align="center" rowspan="1" colspan="1">31 (32.0%)</td><td align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker</td><td align="center" rowspan="1" colspan="1">55 (55.0%)</td><td align="center" rowspan="1" colspan="1">57 (58.8%)</td><td align="center" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1">Family history of CAD</td><td align="center" rowspan="1" colspan="1">26 (26.0%)</td><td align="center" rowspan="1" colspan="1">24 (24.7%)</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior angina or myocardial infarction</td><td align="center" rowspan="1" colspan="1">26 (26.0%)</td><td align="center" rowspan="1" colspan="1">25 (25.8%)</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior PCI</td><td align="center" rowspan="1" colspan="1">22 (22.0%)</td><td align="center" rowspan="1" colspan="1">24 (24.7%)</td><td align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Prior CABG</td><td align="center" rowspan="1" colspan="1">5 (5.0%)</td><td align="center" rowspan="1" colspan="1">9 (9.3%)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnosis on admission</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;STEMI</td><td align="center" rowspan="1" colspan="1">48 (48.0%)</td><td align="center" rowspan="1" colspan="1">32 (33.0%)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;NSTEMI</td><td align="center" rowspan="1" colspan="1">5 (5.0%)</td><td align="center" rowspan="1" colspan="1">11 (11.3%)</td><td align="center" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;UAP</td><td align="center" rowspan="1" colspan="1">47 (47.0%)</td><td align="center" rowspan="1" colspan="1">54 (55.7%)</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1">TIMI risk score</td><td align="center" rowspan="1" colspan="1">3.6 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">3.9 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">Medication</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Statin</td><td align="center" rowspan="1" colspan="1">23 (23.0%)</td><td align="center" rowspan="1" colspan="1">26 (26.8%)</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Antiplatelet agent </td><td align="center" rowspan="1" colspan="1">38 (38.0%)</td><td align="center" rowspan="1" colspan="1">49 (50.5%)</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;ACEI/ARB</td><td align="center" rowspan="1" colspan="1">48 (48.0%)</td><td align="center" rowspan="1" colspan="1">38 (39.2%)</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;CCB</td><td align="center" rowspan="1" colspan="1">36 (36.0%)</td><td align="center" rowspan="1" colspan="1">35 (36.1%)</td><td align="center" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;
<italic>&#x003b2;</italic>-blocker</td><td align="center" rowspan="1" colspan="1">15 (15.0%)</td><td align="center" rowspan="1" colspan="1">27 (27.8%)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline laboratory data</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;LDL-C (mg/dL)</td><td align="center" rowspan="1" colspan="1">130.1 &#x000b1; 31.3</td><td align="center" rowspan="1" colspan="1">131.9 &#x000b1; 27.7</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;HDL-C (mg/dL)</td><td align="center" rowspan="1" colspan="1">45.6 &#x000b1; 12.0</td><td align="center" rowspan="1" colspan="1">46.2 &#x000b1; 11.0</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">122.9 &#x000b1; 71.3</td><td align="center" rowspan="1" colspan="1">124.4 &#x000b1; 71.7</td><td align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;eGFR (mL/min/1.73&#x02009;m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">57.2 &#x000b1; 16.0</td><td align="center" rowspan="1" colspan="1">58.9 &#x000b1; 18.3</td><td align="center" rowspan="1" colspan="1">0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;UA (mg/dL)</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">5.9 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">0.63</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;HbA1c (%)</td><td align="center" rowspan="1" colspan="1">6.2 &#x000b1; 1.5</td><td align="center" rowspan="1" colspan="1">6.3 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">0.62</td></tr></tbody></table><table-wrap-foot><fn><p>BMI: body mass index, CAD: cardiovascular disease, PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-segment elevation myocardial infarction, UAP: unstable angina pectoris, TIMI risk score: thrombolysis in myocardial ischemia risk score, ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker, CCB: calcium channel blocker, LDL-C: low-density lipoprotein cholesterol, HDL-C: high-density lipoprotein cholesterol, eGFR: estimated glomerular filtration rate, UA: uric acid, and HbA1c: hemoglobin A1c.</p></fn></table-wrap-foot></table-wrap></floats-group></article>